← Back to Search

Other

SRF617 for Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by Coherus Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up months 6 and 12
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a combination of three medicines to see if they are safe and effective for patients with advanced prostate cancer that doesn't respond to standard treatments. The medicines work together to help the immune system find and attack cancer cells. The goal is to improve treatment options for these patients.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~months 6 and 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and months 6 and 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Adverse Events (AEs)
Number of Participants With Response
Secondary study objectives
Disease Control Rate (DCR)
Duration of Response (DOR)
Landmark PFS Rate
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SRF617 in combination with etrumadenant and zimberelimabExperimental Treatment3 Interventions
All patients will receive SRF617 administered in combination with etrumadenant (AB928) and zimberelimab (AB122).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SRF617
2020
Completed Phase 1
~90
etrumadenant
2018
Completed Phase 1
~50
zimberelimab
2019
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Coherus Biosciences, Inc.Lead Sponsor
17 Previous Clinical Trials
3,573 Total Patients Enrolled
Surface OncologyIndustry Sponsor
5 Previous Clinical Trials
674 Total Patients Enrolled
Arcus Biosciences, Inc.Industry Sponsor
42 Previous Clinical Trials
7,070 Total Patients Enrolled
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top